Method to evaluate the binding between active ingredients and targets acting on Interleukin 21

Abstract

Research on drugs targeting Interleukin 21 (IL-21) is a pivotal focus in contemporary medical studies. IL-21, a key immune system cytokine, is under scrutiny for its regulatory role in immune responses. Studies aimed to develop drugs that interact with IL-21 to open new avenues for treating immune-related diseases, including inflammation, autoimmune disorders, and cancer. The goal was to enhance our understanding and devise innovative treatments by leveraging the influence of drugs on IL-21.